Despite the many potential advantages of Ad vectors for vaccine application, full utility of current Ad vaccines may be limited by the host anti-vector immune response. Specifically, the anti-Ad humoral immunity abrogates the effectiveness of subsequent administrations of the Ad vector, confounding expression of the encoded transgene, and thus practically restricting the gains that might be accrued via booster effect. In order to exploit the inherent antigenicity of the Ad vector we have developed a vaccination approach based on incorporation of the immunizing antigen epitope directly into the Ad capsid. This novel paradigm is based upon Ad presenting the antigen as a component of the capsid rather than an encoded transgene. Incorporation of immunogenic peptides into the Ad capsid offers potential advantages. Most noteworthy, the processing of the capsid incorporated antigen via the exogenous pathway should result in a strong humoral response akin to the response provoked by native Ad capsid proteins. In addition, since anti-Ad capsid responses are augmented by repeated vector administration, immune responses against antigenic epitopes that are part of the Ad capsid should be augmented by repeated administration as well, thus allowing boosting. These considerations suggest that this novel capsid-incorporated antigen approach may offer exciting potentials to realize Ad-based vaccine strategies that circumvent the major limitations associated with Ad vectors. Critical to the realization of this approach is to define the optimal configuration of antigen in the adenoviral capsid context. To this end, we have established several key technologies that will enable us to reach our goal. In particular, we have developed the means to incorporate heterologous peptide epitopes within the surface-exposed domains of the major Ad capsid protein hexon. We have begun to determine the size and structural factors that predicate functional utility of these domains in the hexon. In addition, we have developed the means to apply cryoelectron microscopy (cryoEM) single particle reconstruction methods to allow us to explore the capsid-incorporated peptide localization with unprecedented, subnanometer resolution. Based on these technologies, we will be able to establish the critical correlates between antigen locale/accessibility within the capsid context and vaccine efficacy. On the basis of these established feasibilities, we hypothesize that Ad vectors can be created with novel capsid-incorporated antigens that can serve as vaccine agents against HIV in animal models. CryoEM-guided capsid design will be applied to develop an optimized vector with optimal anti-HIV immunization. We envision that our proposed structural studies will provide complementary information to in vitro assays and biological readouts and thereby will enable us to understand the functional determinants of incorporated HIV epitopes. This project will design new and innovative methodologies to create HIV vaccines, in hopes of preventing the spread of HIV disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants Phase II (R33)
Project #
Application #
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Pensiero, Michael N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Williams, Briana Jill; Bhatia, Shilpa; Adams, Lisa K et al. (2012) Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One 7:e46981
Hangalapura, Basav N; Timares, Laura; Oosterhoff, Dinja et al. (2012) CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J Gene Med 14:416-27
Flatt, Justin W; Fox, Tara L; Makarova, Natalia et al. (2012) CryoEM visualization of an adenovirus capsid-incorporated HIV antigen. PLoS One 7:e49607
Makarova, Natalia; Zhao, Chunxia; Zhang, Yuanyuan et al. (2011) Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model. PLoS One 6:e18272
Hangalapura, Basav N; Oosterhoff, Dinja; de Groot, Jan et al. (2011) Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 71:5827-37
Gamble, Lena J; Matthews, Qiana L (2010) Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther 5:9-26
Matthews, Qiana L; Fatima, Aiman; Tang, Yizhe et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5:e11815